Condition
Pseudomonas Infection
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 3 (1)
Trial Status
Completed3
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT00027183CompletedPrimary
Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa
NCT02178254Phase 1CompletedPrimary
Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects
NCT00910351Phase 1CompletedPrimary
Cipro Inhaler for Cystic Fibrosis Children Ages 6-12
NCT00529282Phase 3Terminated
A Study of Ceftobiprole in Patients With Fever and Neutropenia.
Showing all 4 trials